Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (Nasdaq: QSI) is a proteomics technology and life sciences company focused on single-molecule protein analysis and Next-Generation Protein Sequencing. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Quantum-Si’s benchtop protein sequencing platform, chemistry kits, and data analysis tools are evolving over time.
Recent Quantum-Si news has highlighted product launches such as the V4 Sequencing Kit, which the company reports improves sequencing coverage through additional amino acid recognition, specialized enzymes, and enhanced algorithms. The company has also announced a Version 3 Library Preparation Kit designed for lower protein input and detection of low-abundance proteins, along with data analysis enhancements that unlock detection of additional amino acids and improve peptide alignment and protein inference.
Investors and researchers can use this page to track updates on Quantum-Si’s Proteus platform development, including prototype sequencing milestones, technology roadmap disclosures, and plans related to amino acid coverage, controlled cleavage chemistry, and post-translational modification methods. Financial news items, such as quarterly earnings releases, capital raising transactions, and lease or other material agreements disclosed via Form 8-K, also appear in this feed.
In addition, the news stream captures corporate governance and human capital updates, including inducement grants under the company’s 2023 Inducement Equity Incentive Plan, investor conference participation, and Investor & Analyst Day events. Bookmark this page to review Quantum-Si’s official press releases and regulatory news in one place, with a focus on developments that shape the company’s proteomics technology, commercialization efforts, and capital markets activity.
Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company™, has announced its participation in an upcoming DNAnexus webinar focused on proteomics in multi-omics research. The virtual event, scheduled for March 25, 2025, at 8 a.m. PT/11 a.m. ET, will explore how integrating proteomics data with other omics datasets drives new discoveries in disease research, including cancer.
Featured speakers include Meredith Carpenter, PhD from Quantum-Si, Cindy Lawley, PhD from Olink, Thermo Fisher Scientific, and Theresa Wohlever from DNAnexus. The webinar will cover:
- The growing impact of proteomics in multi-omics analysis
- Applications for cancer and other disease research
- Technologies and strategies for large-scale discovery and data analysis
- Tools for orthogonal validation of proteins of interest
Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company™, has announced its participation in an upcoming DNAnexus webinar focused on proteomics in multi-omics research. The virtual event, scheduled for March 25, 2025, at 8 a.m. PT/11 a.m. ET, will explore how integrating proteomics data with other omics datasets drives new discoveries in disease research, including cancer.
Key speakers include Meredith Carpenter, PhD from Quantum-Si, Cindy Lawley, PhD from Olink, Thermo Fisher Scientific, and Theresa Wohlever from DNAnexus. The webinar will cover:
- The growing impact of proteomics in multi-omics analysis
- Applications for cancer and other disease research
- Technologies and strategies for large-scale discovery and data analysis
- Tools for orthogonal validation of proteins of interest
Quantum-Si (Nasdaq: QSI) has announced new employee inducement grants approved by its Board's Compensation Committee. The company granted 20,833 restricted stock units (RSUs) to new employees under its 2023 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vesting schedule includes 25% vesting on March 20, 2026, with the remaining portion vesting in 12 equal quarterly installments thereafter. Vesting is contingent upon continued employment with Quantum-Si. These equity awards are specifically designed for new hires who were not previously employed by the company, serving as an inducement for joining Quantum-Si.
Quantum-Si (QSI) reported strong Q4 and full year 2024 financial results, achieving its first quarterly revenue over $1 million. Q4 revenue reached $1.2 million with a 51% gross margin, while full-year 2024 revenue totaled $3.1 million, representing 183% year-over-year growth.
The company successfully raised over $86 million in capital between Q4 2024 and early 2025, extending its cash runway into H2 2027. Key developments include the launch of Platinum® Pro in January 2025, new v2 Library Preparation Kit, and Barcoding Kit in December 2024. QSI reported a Q4 net loss of $33.1 million and full-year net loss of $101.0 million.
With $209.6 million in cash and investments as of December 31, 2024, QSI expects significant revenue growth in 2025, supported by new commercial partnerships with Avantor and international distributors.
Quantum-Si (QSI) and several researchers will present new research and applications at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting from February 23-26th. The presentations will include three scientific posters showcasing Next-Generation Protein Sequencing (NGPS™) innovations:
1. Dr. Meredith Carpenter from Quantum-Si will present how NGPS detects protein-level changes and post-translational modifications
2. Dr. Gloria Sheynkman from University of Virginia will demonstrate the integration of long-read RNA sequencing with the Platinum™ benchtop instrument for single-molecule peptide sequencing
3. Dr. Winston Timp from Johns Hopkins University will showcase how NGPS enables direct peptide sequencing to identify protein partners, offering a cost-effective alternative to legacy technologies
Quantum-Si (Nasdaq: QSI) announces its participation at the US Human Proteome Organization's 2025 conference in Philadelphia, featuring advances in Next-Generation Protein Sequencing™ (NGPS™). The company is sponsoring a panel discussion titled 'Breaking Boundaries: How Next-Generation Protein Sequencing™ is Shaping the Future of Proteomics' on February 25.
The event will showcase research using Quantum-Si's Platinum® Pro benchtop instrument, including new protein barcoding and library preparation solutions. Notable researchers from Washington University, University of Illinois Chicago, and University of Michigan will discuss NGPS's impact on proteomics.
Four scientific posters will be presented, covering: tropomyosin isoform differentiation, reduced protein input requirements, peptide variant mixture measurement, and protein barcoding for multiplexed analysis.
Quantum-Si (QSI) has announced it will release its fourth quarter and full year 2024 financial results on Monday, March 3, 2025. The company will host a conference call and webcast at 4:30 PM ET on the same day, featuring President and CEO Jeff Hawkins and CFO Jeff Keyes, who will discuss the financial results and provide a business update.
Interested participants can join via webcast through the Investors section of Quantum-Si's website under Events and Presentations, or register for a personalized dial-in number. A replay of the event will be available afterward.
Quantum-Si (Nasdaq: QSI) announces a new preprint from Northwestern University researchers demonstrating the combined use of their Next-Generation Protein Sequencing™ (NGPS™) technology and Individual Ion Mass Spectrometry (I2MS) for analyzing interleukin-6 (IL-6), a key immune regulator and therapeutic target.
The study reveals that NGPS provided single amino acid resolution for IL-6 peptide fragments critical to receptor binding and function, while I2MS enabled intact proteoform detection and localized modifications, including glycosylation. The combination of these technologies offers comprehensive coverage of IL-6's structural and functional diversity, potentially advancing therapeutic research in complex diseases like cancer and autoimmune disorders.
Quantum-Si (Nasdaq: QSI) has announced the formation of its Scientific Advisory Board (SAB) to guide its next-generation proteomic technologies development. Dr. Gloria M. Sheynkman, Assistant Professor at the University of Virginia, has been appointed as Chair of the SAB. The board includes distinguished experts in proteomics, genomics, bioinformatics, chemistry, and engineering.
Key board members include Dr. Benjamin A. Garcia from Washington University School of Medicine, Dr. Bradley L. Pentelute from MIT, and Dr. Denis Zaccarin, former Senior VP of R&D at PacBio. The SAB will focus on shaping scientific strategy, identifying emerging trends, and strengthening scientific community engagement. They will also support Quantum-Si in prioritizing applications and fostering collaborations for their next-generation protein sequencing (NGPS) technology and Proteus™ platform.
Quantum-Si (Nasdaq: QSI) has announced a strategic partnership with IDEX Health & Science for the development and manufacturing of the optics module for their Proteus™ proteomics platform. IDEX Health & Science, a global leader in life science optics, fluidics, and microfluidics, will leverage their expertise through their Melles Griot and Semrock product lines to support the design, development, and manufacturing of the Proteus optics module.
The partnership aims to utilize IDEX's experience in complex optical systems for life sciences instrumentation, with QSI targeting to bring the novel platform to market by the second half of 2026. The collaboration is expected to accelerate scientific advancements and mitigate risks associated with timelines and product launches, ultimately contributing to breakthroughs in drug discovery, diagnostics, and human health.